| Title |
Ruxolitinib as an emerging treatment in myelofibrosis
|
|---|---|
| Published in |
Blood and Lymphatic Cancer: Targets and Therapy, March 2013
|
| DOI | 10.2147/blctt.s24926 |
| Authors |
Ruben Mesa, Robyn Emanuel, Geyer |
Mendeley readers
The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 1 | 33% |
| Student > Master | 1 | 33% |
| Unknown | 1 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 1 | 33% |
| Nursing and Health Professions | 1 | 33% |
| Unknown | 1 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2013.
All research outputs
#23,100,963
of 25,748,735 outputs
Outputs from Blood and Lymphatic Cancer: Targets and Therapy
#1
of 1 outputs
Outputs of similar age
#183,163
of 207,082 outputs
Outputs of similar age from Blood and Lymphatic Cancer: Targets and Therapy
#1
of 1 outputs
Altmetric has tracked 25,748,735 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1 research outputs from this source. They receive a mean Attention Score of 0.2. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,082 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them